3 Papers
11 Citations
Andy Young is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Obestatin & Internal medicine. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
RETRACTED: Obestatin reduces food intake and suppresses body weight gain in rodents
TL;DR: Interestingly, the dose-response relationship was U-shaped such that both low and high doses were without effect in either species and may explain the difficulties in reproducing the effects of obestatin on feeding reported by some groups.
141
Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues
Mark D. Rosen,Hariharan Venkatesan,Hillary M Peltier,Scott D. Bembenek,Kimon C. Kanelakis,Lucy X. Zhao,Barry Eastman Leonard,Frances M. Hocutt,Xiaodong Wu,Heather L. Palomino,Theresa I. Brondstetter,Peter V. Haugh,Laurence Cagnon,Wen Yan,Lisa A. Liotta,Andy Young,Tara Mirzadegan,Nigel P. Shankley,Terrance D. Barrett,Michael H. Rabinowitz +19 more
TL;DR: Certain benzimidazole-2-pyrazole carboxylates were discovered to be PHD2 inhibitors using ligand- and structure-based methods and found to be potent, orally efficacious stimulators of erythropoietin secretion in vivo.